Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study
2023 · The Lancet Neurology · 216 citations
https://doi.org/10.1016/s1474-4422(23)00194-1